Pax-3 Antibody (A-5): sc-376215
- Pax-3 Antibody (A-5) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 387-425 near the C-terminus of Pax-3 of human origin
- recommended for detection of Pax-3 of mouse, rat, human and origin by WB, IP, IF and ELISA; also reactive with additional species, including and equine, bovine, porcine and avian
- TransCruz reagent for ChIP application (sc-376215 X, 200 µg/0.1 ml)
- See Pax-3/7 (B-5): sc-365843 for Pax-3 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Pax-3 Antibody (A-5) for WB applications. These reagents are now offered in bundles with Pax-3 Antibody (A-5) (see ordering information below).
Pax-3 (A-5) is a mouse monoclonal IgG1 antibody. PAX3 contains paired domains sharing strong homology to Drosophila genes involved in early development programming. PAX3 functions as a DNA-binding protein expressed during early neurogenesis, containing both a paired domain and a paired-type homeodomain. During early neurogenesis, PAX3 expression remains limited to mitotic cells in the ventricular zone of the developing spinal cord and specific regions in the hindbrain, midbrain, and diencephalon. In 10-12 day embryos, PAX3 expression appears in neural crest cells of the developing spinal ganglia, craniofacial mesectoderm, and limb mesenchyme. Mutations in MITF and PAX3 genes, which encode transcription factors, cause Waardenburg syndrome II (WSII) and WSI/WSIII, respectively.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Pax-3 Antibody (A-5) References:
- PAX3-FOXO1 fusion gene in rhabdomyosarcoma. | Linardic, CM. 2008. Cancer Lett. 270: 10-8. PMID: 18457914
- Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. | Kubic, JD., et al. 2008. Pigment Cell Melanoma Res. 21: 627-45. PMID: 18983540
- Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. | Goulding, MD., et al. 1991. EMBO J. 10: 1135-47. PMID: 2022185
- PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. | Gryder, BE., et al. 2017. Cancer Discov. 7: 884-899. PMID: 28446439
- PAX3 silencing suppresses gastric cancer proliferation and angiogenesis via MET/PI3K signaling. | Lv, WL., et al. 2020. Neoplasma. 67: 304-311. PMID: 31847528
- An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. | Zagozewski, J., et al. 2020. Nat Commun. 11: 3627. PMID: 32686664
- Biphenotypic sinonasal sarcoma with PAX3/FOXO1 fusion. | Tosun, I., et al. 2023. Pol J Pathol. 74: 282-285. PMID: 38477090
- TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma. | Gallo-Oller, G., et al. 2024. Exp Hematol Oncol. 13: 38. PMID: 38581035
- Pax-3 expression in segmental mesoderm marks early stages in myogenic cell specification. | Williams, BA. and Ordahl, CP. 1994. Development. 120: 785-96. PMID: 7600957
- Competence, specification and induction of Pax-3 in the trigeminal placode. | Baker, CV., et al. 1999. Development. 126: 147-56. PMID: 9834194
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pax-3 Antibody (A-5) | sc-376215 | 200 µg/ml | $322.00 | |||
Pax-3 Antibody (A-5): m-IgG Fc BP-HRP Bundle | sc-537980 | 200 µg Ab; 10 µg BP | $361.00 | |||
Pax-3 Antibody (A-5): m-IgGκ BP-HRP Bundle | sc-535478 | 200 µg Ab; 40 µg BP | $361.00 | |||
Pax-3 Antibody (A-5): m-IgG1 BP-HRP Bundle | sc-545474 | 200 µg Ab; 20 µg BP | $361.00 | |||
Pax-3 (A-5) Neutralizing Peptide | sc-376215 P | 100 µg/0.5 ml | $69.00 | |||
Pax-3 Antibody (A-5) X | sc-376215 X | 200 µg/0.1 ml | $322.00 |